PPIDT00435

Drug Information
NameElranatamab
SequenceEVQLVESGGGLVQPGGSLRLSCAASGFTFSDYYMTWVRQAPGKGLEWVAFIRNRARGYTSDHNPSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDRPSYYVLDYWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCRVRCPRCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVAVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPSSIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSRLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
DrugBank_IDDB15395
Typebiotech
IndicationElranatamab is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma. In the US, it is approved in patients who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.[L47815] In Europe, it is approved in patients who received at least three prior therapies.[L50432] In the US, elranatamab is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).[L47815]
Dosage Forms
Form Route Strength
Injection, solution Subcutaneous
40 mg/ml
Injection, solution Subcutaneous
44 mg/1.1mL
Injection, solution Subcutaneous
76 mg/1.9mL
Solution Subcutaneous
44 mg / 1.1 mL
Solution Subcutaneous
76 mg / 1.9 mL
Target Information
Role Uniprot_ID Gene_Name Entity_Name Organism Actions Internal link
target Q02223 TNFRSF17 Tumor necrosis factor receptor superfamily member 17 Homo sapiens antibody Link
target P04234 CD3D T-cell surface glycoprotein CD3 delta chain Homo sapiens antibody Link